217 related articles for article (PubMed ID: 33968052)
1. Chimerism, the Microenvironment and Control of Leukemia.
Deeg HJ
Front Immunol; 2021; 12():652105. PubMed ID: 33968052
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
5. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
7. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
[TBL] [Abstract][Full Text] [Related]
8. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
9. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell transplantation and cellular therapy.
Kolb HJ
HLA; 2017 May; 89(5):267-277. PubMed ID: 28371460
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
12. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
13. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses.
Das R; Komorowski R; Hessner MJ; Subramanian H; Huettner CS; Cua D; Drobyski WR
Blood; 2010 Jun; 115(25):5249-58. PubMed ID: 20382845
[TBL] [Abstract][Full Text] [Related]
14. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
15. New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.
Deeg HJ
Int J Hematol; 2003 Jan; 77(1):15-21. PubMed ID: 12568295
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL.
Nash RA; Storb R
Curr Opin Immunol; 1996 Oct; 8(5):674-80. PubMed ID: 8902393
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease in mini-transplant.
Mineishi S; Schuening FG
Leuk Lymphoma; 2004 Oct; 45(10):1969-80. PubMed ID: 15370240
[TBL] [Abstract][Full Text] [Related]
19. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
Hadjis AD; McCurdy SR
Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
[TBL] [Abstract][Full Text] [Related]
20. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]